A COVID-19 vaccine that doesn't need to be kept at very low temperatures has been found to be 70 per cent effective on average, with potential for that to rise to 90 per cent depending on how the doses are given. In large-scale trials of more than 20,000 people in the UK and Brazil, 131 people became infected by the disease, according to preliminary results published this week by the vaccine's developers, AstraZeneca and the University of Oxford. "We have a vaccine for the world. We've got a vaccine that's highly effective: it prevents severe disease and hospitalisation," Andrew Pollard at the University of Oxford told an online press conference.
展开▼
